Ares(2019)1616421
Ref. Ares(2019)2527775 - 10/04/2019
____________________________________________
From: [Art 4.1(b)]
(TRADE)
Sent: Thursday, September 06, 2018 5:44 PM
To: [Art 4.1(b)] (TRADE); [Art 4.1(b)] (TRADE); [Art 4.1(b)] (TRADE); [Art 4.1(b)] (TRADE)
Cc: [Art 4.1(b)]
(TRADE); [Art 4.1(b)] (TRADE); VERLY Johan (CAB-MALMSTROM);
BURGSMUELLER Christian (CAB-MALMSTROM)
Subject: FLASH: meeting HoC Mia Åsenius and Eli Lilly [Art 4.1(b)]
Today Head of Cabinet Ms Åsenius met the [Art of Eli Lilly (a multinational pharmaceutical
4.1(b)]
company) Mr [Art 4.1(b)] (
[Art 4.1(b)]
.
The main subject of the meeting was the EU-US trade relations, with a specific focus on the
intellectual property (IP). Overall, the pharma industry is one of the main advocates for a
stronger EU-US cooperation.
[Art 4.1(a)]
Mr
hig
[Art 4.1(b)]
hlighted that the pharma industry has one main interest in trade
agreements – a strong IP chapter. Therefore, an EU-US agreement should also have such a
chapter. Ms Åsenius explained that it is not foreseen to re-start TTIP negotiations and an
agreement of more restricted scope would have more chances of being agreed.
The rest of the document is redacted as out of scope
.
Ares(2019)1616421
[Art 4.1(b)]
<< OLE Object: Picture (Device Independent Bitmap) >>
European Commission
Directorate General Trade
Unit B3 Intellectual Property and Public Procurement
1049 Brussels, Belgium
office: CHAR [Ar
, tel.: +
t 4.1(b)] 32-2-2[Art 4.1(b)]
e-mail: [Art 4.1(b)] @ec.europa.eu
_________________________________________________
The views expressed in this e-mail are my own and may not,
under any circumstances, be interpreted as stating an official
position of the European Commission.